Page 10 - Josh Nathan Kazis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FDA Approves First Two Sickle Cell Gene Therapies

The Food and Drug Administration on Friday approved two gene therapies to treat patients with sickle cell disease. The new treatments, one developed by.

United statesJosh nathan kazisDrug administration onVertex pharmaceuticalsDrug administrationNobel prizeArticle normalBiotechnology servicesCancer drugsTrusts funds financial vehiclesPrivate equityScientific research servicesHealthcare life sciencesAlternative investmentsBusiness consumer servicesBiological therapy

White House Plan to Cut Drug Prices Gets Shrugs From Investors

The Biden administration unveiled a plan to force drugmakers to license generic versions of patented drugs. Stocks barely budged.

United statesWhite houseDistrict of columbiaPeter maybardukRaymond jamesJosh nathan kazisModerna covidAstellas pharmaAaron kesselheimChris meekinsNational institutes of healthHealth forumPharmaceuticals industryMy administrationHarvard medical schoolDrug administration

Pfizer s Obesity Pill Disappointed Biotech Rivals Are Rubbing Their Hands

Pfizer expects the market for new obesity pills to be $90 billion per year. Lilly, Novo, and many biotechs hope to claim chunks of it.

United statesEli lillyRoche holdingannouncedChris shibutaniJay olsonJosh nathan kazisGoldman sachsNovo nordiskTerns pharmaceuticalsViking therapeuticsStructure therapeuticsCarmot therapeuticsArticle normalBiotechnology servicesAgricultural machineryHealthcare life sciences

Pfizer s Weight-Loss Pill Disappointment Is an Opening for Biotech Rivals

Pfizer s Weight-Loss Pill Disappointment Is an Opening for Biotech Rivals
marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.

United statesJosh nathan kazisRoche holdingannouncedChris shibutaniEli lillyJay olsonGoldman sachsTerns pharmaceuticalsNovo nordiskViking therapeuticsStructure therapeuticsCarmot therapeutics

Cigna, Humana Merger: Why Wall Street Hates the Idea

Investors got a glimpse of a potential mega-merger between Cigna and Humana, two large health insurers. They didn’t like what they saw.

United statesJohn ransomwroteMizuho holzJoe buglewicz bloombergRaymond jamesKevin fischbeckJared holzJosh nathan kazisAnn hynesUnitedhealth groupCigna groupWall street journalWall streetMedicare advantage focusedWhile cignaMedicare advantage